News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation Technology
Peptelligence® technology currently used in Oral KORSUVA™ formulation STAMFORD, Conn. , Aug. 21, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of
View HTML
Toggle Summary Cara Therapeutics Reports Second Quarter 2019 Financial Results
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa
View HTML
Toggle Summary Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019
STAMFORD, Conn. , July 31, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the
View HTML
Toggle Summary Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
STAMFORD, Conn. , July 29, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today
View HTML
Toggle Summary Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock
STAMFORD, Conn. , July 24, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today
View HTML
Toggle Summary Cara Therapeutics Announces Proposed Offering of Common Stock
STAMFORD, Conn. , July 24, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today
View HTML
Toggle Summary Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment
- Study now fully enrolled; topline data expected in 4Q 2019 - STAMFORD, Conn. , July 22, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively
View HTML
Toggle Summary Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA™ (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis
STAMFORD, Conn. , July 09, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the
View HTML
Toggle Summary Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAᵀᴹ (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC)
Completed Phase 1 trial in patients with hepatic impairment established Oral KORSUVA tablet strength STAMFORD, Conn., June 26, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to
View HTML
Toggle Summary Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference
STAMFORD, Conn. , May 31, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a
View HTML